Latest News

• Reminder - Webinar Thursday!        

  Please join us on Thursday, September 18 at 7pm ET for "BRAF-Targeted Therapies for Brain Tumors" with Dr. Karisa Schreck.  

  
  
• Journal of Neuro-Oncology Publishes New Data Reinforcing GammaTile® Efficacy in Treating Recurrent Brain Metastases        

  A new study from MD Anderson Cancer Center reports promising outcomes using GammaTile (cesium-131 collagen tile) brachytherapy for brain metastases recurring after prior stereotactic radiosurgery (SRS). Among 31 patients with brain metastases, most commonly from breast (37%) or non-small cell lung cancer (26%), all underwent surgical resection with GammaTile placement. Gross total resection was achieved in 84% of cases. At a median follow-up of 11.8 months, local failure occurred in 13% overall and just 6.4% when complete resection was achieved. One-year overall survival was 65.8%, with low toxicity—only 8% developed grade 2+ radiation necrosis. Subtotal resection, tumor volume, multiple prior radiation courses, and dural contact were associated with higher failure risk. These results support GammaTile as a potential effective, low-toxicity salvage option for recurrent brain metastases.